Medical biotechnology is our topic.

Slides:



Advertisements
Similar presentations
COMMERCIAL OPPORTUNITIES IN GERMANY
Advertisements

Market Research and business connection project Organized by: ELP Business Connections Switzerland ELP Partners in Italy COMMERCIAL OPPORTUNITIES IN ITALY.
Regulation of Advanced Therapies A Biotech SME Perspective May 11, 2006 Gil Beyen CEO - TiGenix N.V. Member of the EuropaBio Advanced Therapies.
South Africa’s S&T partnership with the European Union From FP4 to Horizon 2020 Daan du Toit Senior S&T Representative to the EU.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Advancing technology and science companies. The Neem Tree is fast-growing and can thrive even in difficult drought-like conditions. Like the rapidly growing.
The 5th Globelics Academy Ph.D. School on ‘ National Innovation Systems and Economic Development ’ 2–14 June, 2008, Tampere – Finland Nejla YACOUB Nejla.
Moscow, German-Russian Co-operation Network Biotechnology1 German-Russian Cooperation Network Biotechnology successful cooperation between Russia.
Centre for Innovation, Technology Transfer and University Development Jagiellonian University Centre for Innovation, Technology Transfer and University.
European Technology Platform – Innovative Medicines for Europe 1 st Workshop on Education and Training, 24 & 25 February 2005 Educational gaps in the R&D.
Introducing The Most Versatile Educational Product…EVER! Now Friendly.
Health Information Day, 22. November 2013 Enterprise Europe Network Martine DISS, Head of Unit, EACI and Hicham ABGHAY, Steinbeis-Europa-Zentrum, DE.
Part 2  In community-based long-term care, the resident may simply need assistance with taking their medications at the right time or with preparing.
Pharmacy Administration By Dr. Shaimaa Mahmoud Nashat Canadian equivalent Master Degree in Clinical Pharmacy - Toronto University – Canada Canadian Board.
European Parliament Advanced Therapies Hearing May 11, 2006 Advanced Therapies The proposed EU regulation from the viewpoint of a Pharmaceutical company.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
« How to succeed in doing a cluster strategy? » DICK Marie-Noëlle Cluster software.brussels.
Nathan Tinker Executive Director New York Biotechnology Association New York BizBio 2009 Fighting for a Healthy Biotech Industry.
World Marketing Conference January 12, An initiative of KKL-JNF  Nurture a KKL-JNF young, professional, sustainability-oriented leadership 
INTRODUCTION TO RA.
How to Access a Promising Market? Challenges from the Viewpoint of an Entrepreneur Interested to Access the Indian Market Norbert Gerbsch, PhD Head of.
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.
Polish Technology Platform for Biotechnology Partnering Meeting in Birini, Presented by Zygmunt Krasiński National Contact Point for Research.
Www. kulturwirtschaft.de or Allgemeine Wirtschaftspolitik/Industriepolitik Members of the research group: Michael Söndermann, Büro.
Sustainable Clean Energy. World Nuclear Association 190 Members.
European Commission Introduction to the Community Programme for Employment and Social Solidarity PROGRESS
Sustainability Task Force Kickoff Meeting Oct 2, 2008 By Karen J. Baker.
AIFA European Conference on Clinical Research for Decision Making Sergio Dompé - Farmindustria Rome, March 30th, 2007 Access to market by new medicines.
September 2004 The Franco-German University Responsibilities and Objectives EUPRIO, Malta 2004 Ulrike Reimann.
1 SMEs – a priority for FP6 Barend Verachtert DG Research Unit B3 - Research and SMEs.
A presentation of The Association of the Pharmaceutical Industry in Norway (LMI)
DNA TECHNOLOGIES.
September 2004 Workshop Communicating in two cultures The Franco-German University EUPRIO, Malta 2004 Ulrike Reimann.
EURORDIS Eurordis Position on Research Priorities for Rare Diseases.
A Global Network for Standards Education and Research William E. Kelly Department of Civil Engineering The Catholic University of America Washington, DC.
DESIGN & CREATIVITY WG 10, April 2013 CREATIVE AND CULTURAL INDUSTRIES EVENT.
New medicines, new challenges: the SMC approach
Dr. Samuel Dyer - Chairman of the Board - Medical Science Liaison Society MSL What is a Medical Science Liaison? (What Do.
Safety in Medicines: Raising the profile with the Royal Pharmaceutical Society Liz Rawlins Communications Officer 9 May 2011.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
Introduction to The BECOTEPS project Workshop on the opportunities for new business concepts with the combined non-food biomass chains 7 th October 2009.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Mammalian Cells Bioreactor Market to reach $1.5 bn by 2024
Technological excellence
II Volga specialized forum "Medicine. Pharmacy"
A capacity building programme for patient representatives
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Dr. Siegfried Bialojan Background Skills Professional experience
Clou5 Everything from one source: simple and multifunctional communication and cooperation instrument. The work for the registered networks, will.
Cooperation for Better Regulation
Vesa Tanner European Commission Directorate-General Energy
Strategic Benchmarking Research & Analysis
Gestora brasileiro focada exclusivamente na área da saúde.
The Global Privacy Enforcement Network Why does it matter? The Global Privacy Enforcement Network was established in 2008 The Network.
Introduction to TransCelerate
Improving Vehicle Cybersecurity: ICT Industry Experience & Perspectives Denis Niles Senior Mobile & IoT Security Specialist Wireless Devices & Applications.
Introduction to TransCelerate
The International Consortium for Personalised Medicine
National Cluster Platform Austria Dr
Competitiveness of the regional market, importance of statistics and innovations THE ROLE OF RESEARCH CENTERS IN PROMOTING OF RESEARCH Sarajevo, 8th.
Technological excellence
Prairie State Local Government Sustainability Network (PSN)
3rd EU-China IP Academic Forum SHANGHAI 22 November 2018
Ethics and Clinical Ethics Committee
COST and COST Actions Participation of Georgian researchers
New Services for Ageing Well in the Information Society
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Driving the Future of Digital Experiences.
Module No 6: Building Capacity in Rural Micro-Enterprises
Stratified Medicine: Will it be the Future of Medicine?
The International Transport Forum at the OECD
Presentation transcript:

Medical biotechnology is our topic. Picture: ©vfa/Martin Joppen vfa bio represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies (vfa). vfa campaigns for the interests of 42 worldwide leading pharmaceutical companies in the fields of health, research and economy. vfa bio seeks to exploit the therapeutic and economic potential of biotechnology to make Germany the leading biotech location in Europe. Medical biotechnology is our topic. Consequently, we primarily deal with Medical progress provided by biopharmaceuticals – relevance, benefit and value for patients, physicians and society as a whole Access to biopharmaceuticals for patients Business location Germany and regulatory and economic framework for research, development and production of biopharmaceuticals Quality-assured use of biopharmaceuticals – original products and biosimilars Orphan Drugs Advanced therapies such as gene and cell therapies and tissue engineering products

state of the art data and facts in the field of medical biotechnology vfa bio provides state of the art data and facts in the field of medical biotechnology annual report about the situation of medical biotechnology in Germany position papers addressing relevant topics in medical biotechnology strategic recommendations workshops, roundtables and discussion forums contact point for politicians, press and the public platform for the exchange of information forum for cooperations nomination of contact partners for various fields opportunities for networking between member firms advantages of a full range association with full-time top experts in communication, distribution and future projects, legal and international affairs, market and reimbursement as well as research, development and innovation vfa bio has 30 member companies. Kontakt: Dr. Siegfried Throm Dr. Sabine Sydow Dr. Rolf Hömke Geschäftsführer vfa bio Leiterin vfa bio Wissenschaftspresse Telefon 030 20604-300 Telefon 030 20604-310 Telefon 030 20604-204 S.Throm@vfa.de S.Sydow@vfa.de R.Hoemke@vfa.de